Logo image of IPSC

CENTURY THERAPEUTICS INC (IPSC) Stock Fundamental Analysis

USA - NASDAQ:IPSC - US15673T1007 - Common Stock

0.5348 USD
-0.01 (-0.96%)
Last: 11/7/2025, 8:00:02 PM
0.5267 USD
-0.01 (-1.51%)
After Hours: 11/7/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, IPSC scores 3 out of 10 in our fundamental rating. IPSC was compared to 534 industry peers in the Biotechnology industry. IPSC has a great financial health rating, but its profitability evaluates not so good. IPSC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IPSC has reported negative net income.
In the past year IPSC has reported a negative cash flow from operations.
In the past 5 years IPSC always reported negative net income.
In the past 5 years IPSC reported 4 times negative operating cash flow.
IPSC Yearly Net Income VS EBIT VS OCF VS FCFIPSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of IPSC (-8.18%) is better than 84.64% of its industry peers.
Looking at the Return On Equity, with a value of -11.09%, IPSC belongs to the top of the industry, outperforming 87.64% of the companies in the same industry.
Industry RankSector Rank
ROA -8.18%
ROE -11.09%
ROIC N/A
ROA(3y)-33.55%
ROA(5y)-34.54%
ROE(3y)-65.22%
ROE(5y)-58.59%
ROIC(3y)N/A
ROIC(5y)N/A
IPSC Yearly ROA, ROE, ROICIPSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IPSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPSC Yearly Profit, Operating, Gross MarginsIPSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

IPSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPSC has been increased compared to 1 year ago.
IPSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IPSC Yearly Shares OutstandingIPSC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPSC Yearly Total Debt VS Total AssetsIPSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -2.57, we must say that IPSC is in the distress zone and has some risk of bankruptcy.
IPSC has a Altman-Z score (-2.57) which is comparable to the rest of the industry.
IPSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.57
ROIC/WACCN/A
WACC8.75%
IPSC Yearly LT Debt VS Equity VS FCFIPSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

IPSC has a Current Ratio of 10.72. This indicates that IPSC is financially healthy and has no problem in meeting its short term obligations.
IPSC has a Current ratio of 10.72. This is amongst the best in the industry. IPSC outperforms 82.96% of its industry peers.
A Quick Ratio of 10.72 indicates that IPSC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.72, IPSC belongs to the top of the industry, outperforming 82.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.72
Quick Ratio 10.72
IPSC Yearly Current Assets VS Current LiabilitesIPSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

IPSC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.71%, which is quite impressive.
The Revenue has grown by 5483.56% in the past year. This is a very strong growth!
EPS 1Y (TTM)85.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)5483.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

IPSC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.51% yearly.
IPSC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y92.96%
EPS Next 2Y10.57%
EPS Next 3Y4.16%
EPS Next 5Y15.51%
Revenue Next Year3161.57%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

IPSC Yearly Revenue VS EstimatesIPSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2031 2032 20M 40M 60M 80M 100M
IPSC Yearly EPS VS EstimatesIPSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPSC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPSC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPSC Price Earnings VS Forward Price EarningsIPSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPSC Per share dataIPSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.57%
EPS Next 3Y4.16%

More info and screens

0

5. Dividend

5.1 Amount

IPSC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTURY THERAPEUTICS INC

NASDAQ:IPSC (11/7/2025, 8:00:02 PM)

After market: 0.5267 -0.01 (-1.51%)

0.5348

-0.01 (-0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners41.84%
Inst Owner Change-15.08%
Ins Owners3.16%
Ins Owner Change4.14%
Market Cap46.20M
Revenue(TTM)114.13M
Net Income(TTM)-23.28M
Analysts83.64
Price Target5.1 (853.63%)
Short Float %0.57%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)743.69%
Min EPS beat(2)0.92%
Max EPS beat(2)1486.45%
EPS beat(4)4
Avg EPS beat(4)376.63%
Min EPS beat(4)0.1%
Max EPS beat(4)1486.45%
EPS beat(8)6
Avg EPS beat(8)189.71%
EPS beat(12)9
Avg EPS beat(12)128.27%
EPS beat(16)10
Avg EPS beat(16)95.42%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.57%
EPS NY rev (1m)0%
EPS NY rev (3m)58.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS1.32
BVpS2.43
TBVpS2.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.18%
ROE -11.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.55%
ROA(5y)-34.54%
ROE(3y)-65.22%
ROE(5y)-58.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.12%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.72
Quick Ratio 10.72
Altman-Z -2.57
F-Score6
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)156.34%
Cap/Depr(5y)541.5%
Cap/Sales(3y)401.8%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y92.96%
EPS Next 2Y10.57%
EPS Next 3Y4.16%
EPS Next 5Y15.51%
Revenue 1Y (TTM)5483.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year3161.57%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y77.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.59%
OCF growth 3YN/A
OCF growth 5YN/A

CENTURY THERAPEUTICS INC / IPSC FAQ

What is the fundamental rating for IPSC stock?

ChartMill assigns a fundamental rating of 3 / 10 to IPSC.


What is the valuation status of CENTURY THERAPEUTICS INC (IPSC) stock?

ChartMill assigns a valuation rating of 0 / 10 to CENTURY THERAPEUTICS INC (IPSC). This can be considered as Overvalued.


How profitable is CENTURY THERAPEUTICS INC (IPSC) stock?

CENTURY THERAPEUTICS INC (IPSC) has a profitability rating of 2 / 10.


What is the financial health of CENTURY THERAPEUTICS INC (IPSC) stock?

The financial health rating of CENTURY THERAPEUTICS INC (IPSC) is 7 / 10.